June 3, 2022

Sound Biologics Announces Presentations at ASCO 2022 Annual Meeting

PSB205/QL1706, a bifunctional anti-PD-1 and anti-CTLA-4 MabPair product, demonstrates anti-tumor effects with acceptable tolerability and manageable toxicity

BOTHELL, WA, UNITED STATES, June 3, 2022 /EINPresswire.com/ — Sound Biologics (Qilu Puget Sound Biotherapeutic Corp.), an emerging biotechnology company focused on developing a novel MabPair platform for antibody-based combination therapies for the treatment of cancer, inflammation, and autoimmune disease, today announced clinical updates on its first MabPair product PSB205/QL1706 presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (Chicago, June 3-7, 2022).

“The Phase 1a/1b data presented at ASCO provides clinical validation of the first MabPair product,” commented Sound Biologics’ Chief Executive Officer Wei Yan, PhD. “PSB205 demonstrated strong anti-tumor activities of the dual immune checkpoint blockades while maintaining a very tolerable side effect profile, with less adverse events than typically noted in published studies with anti-PD-1 and anti-CTLA-4 combination therapy. This unique profile offers multiple opportunities for further development of PSB205, either as single product or in combination with other molecules.”

View original release on PR Newswire ➤

About PSB205

PSB205 is a first-in-class bifunctional product that contains a mixture of unique anti-PD-1 and anti-CTLA-4 monoclonal antibodies produced by a single cell line via the company’s proprietary MabPair technology. MabPair products offer many advantages over bispecific antibodies. The relative ratio of the two antibodies in the MabPair can be well-controlled, and each antibody is individually engineered for optimal target coverage, effector function, pharmacokinetics, and exposure. The anti-CTLA-4 component of the MabPair is designed with a shorter half-life than currently available anti-CTLA-4 antibodies in an effort to reduce known side effects associated with CTLA-4 blockade. Preclinical studies with PSB205 demonstrated superior efficacy in tumor models compared to either checkpoint inhibitor alone. PSB205 represents a potentially best-in-class immuno-oncology product that promises to exhibit robust combination activity while being significantly more tolerable to patients than currently approved anti-PD-1/anti-CTLA-4 combinations. Parallel Phase 1 studies in a broad range of refractory solid tumors are currently ongoing in China and the United States, and the ASCO-posters represent updated clinical data from these studies.